Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avastin Hearing's Deadline For Written Submissions Is Indefinitely Delayed

This article was originally published in The Pink Sheet Daily

Executive Summary

Presiding Officer Karen Midthun postpones the submission deadline for written summaries of arguments by Genentech and CDER until one week after the formal hearing notice is issued, although it remains unclear when that will occur.
Advertisement

Related Content

CDER Seeks To Limit Evidence On Future Avastin Studies At June Hearing
CDER Seeks To Limit Evidence On Future Avastin Studies At June Hearing
An Avastin Loophole: Hamburg Could Decide To Retain Approval During Confirmatory Trial
An Avastin Loophole: Hamburg Could Decide To Retain Approval During Confirmatory Trial
Roche Succeeds In Changing EMA Ruling On Avastin
Avastin Hearing: Genentech, CDER Dispute Relevance Of Second-Line Breast Cancer Data
Avastin Hearing: Genentech, CDER Dispute Relevance Of Second-Line Breast Cancer Data
Avastin Data, Policy Implications Warrant Hearing On Breast Cancer Use, Genentech Tells FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS072316

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel